Quick answer
PSA doubling time is the time your PSA takes to double. In the expert consensus, it comes from the line of the logarithm of PSA over time, with at least 3 tests over at least 3 months, and it is reported in months.1 After prostatectomy, the 2026 European guideline considers a doubling time of 1 year or less, or ISUP 4 or 5 in the surgical report, as high risk.2 The number helps you understand how fast the PSA is rising, but it is only one part of the decision. Bring the result to your consultation.
Calculate your doubling time
Gather your PSA results since it started to rise, with the date of each test. If you want to see the European risk group, have the surgical pathology report or the biopsy report from before radiotherapy at hand.
Your answers stay in your browser. Nothing is sent, stored or saved in cookies, and everything is cleared when you close the page.
Enter 2 to 6 PSA results, each with the date of the test. The order does not matter.
PSA 1
PSA 2
PSA 3
PSA 4
PSA 5
PSA 6
The calculator uses every test you enter, in any order, and tells you when the series does not meet what the consensus asks for. The month in the calculation is the average calendar month, 30.4 days. If your PSA has risen after surgery, the page on PSA after prostatectomy explains what each value means. Other tools are on the urology calculators page.
How the calculation works
The calculation assumes that PSA rises exponentially, doubling at similar intervals. That is why the PSA Working Group consensus uses the natural logarithm of PSA, which turns this curve into a straight line. The slope of the line shows how fast the PSA is rising, and the doubling time is the natural logarithm of 2 divided by that slope.1
An example worked out by hand: PSA of 0.25 ng/mL, then 0.5, then 1.0, with 6 months between tests. The PSA doubled twice in 12 months, so the doubling time is 6.0 months. The calculator gives the same number.
The consensus also says which tests go into the calculation:1
- values of 0.20 ng/mL or more, with a rising trend (each value does not have to be higher than the one before);
- at least 3 values, over at least 3 months, with at least 4 weeks between tests;
- all values from a period of up to 12 months;
- the same assay for every test, preferably at the same laboratory.
When the PSA is stable or falling, the slope is zero or negative, and there is no doubling time.1
The European recurrence risk groups
The European guideline splits men with biochemical recurrence into two groups, with different rules after surgery and after radiotherapy:2
| Treatment | Low risk | High risk |
|---|---|---|
| After prostatectomy | Doubling time longer than 1 year and ISUP below 4 in the surgical report | Doubling time of 1 year or less, or ISUP 4 or 5 in the surgical report |
| After radiotherapy | Interval to biochemical failure longer than 18 months and ISUP below 4 on biopsy | Interval to biochemical failure of 18 months or less, or ISUP 4 or 5 on biopsy |
The groups came from a review of 77 studies. It showed that PSA recurrence worsens survival mainly in a subgroup: short doubling time and high grade after surgery, and early failure and high grade after radiotherapy.3 In a German study of 1,125 men with recurrence after prostatectomy, the high-risk group had 3.46 times more metastasis and 5.12 times more death from prostate cancer than the low-risk group.4
After radiotherapy, biochemical failure is a rise in PSA of 2 ng/mL or more above the lowest value after treatment, the Phoenix definition. The European guideline speaks of the "interval to biochemical failure" but does not say whether it is counted from the start or the end of radiotherapy.2 The page on PSA rising after radiotherapy explains it.
For the low-risk group, the guideline recommends offering monitoring with PSA (weak recommendation). It also recommends not offering hormone therapy to men without metastases and with a doubling time above 12 months (strong recommendation).2
What the studies show
Doubling time became routine because of studies of men whose PSA came back after prostatectomy. In an American study of 1,997 men who had surgery, 304 had a rising PSA and were followed without hormone therapy until metastasis appeared. The time until the PSA came back, the Gleason grade and the doubling time helped predict the chance of metastasis and the time until it appeared, a median of 8 years after the PSA rise.5
Another study, of 379 men with recurrence after prostatectomy, divided the doubling time into less than 3 months, 3 to 8.9, 9 to 14.9 and 15 months or more. The doubling time, the Gleason score in the surgical report and the time from surgery to PSA recurrence were all risk factors for death from prostate cancer.6 The same study showed that survival can be very long in low-risk cases.
What the calculation does not show
The doubling time changes with the tests that go into it. Too few values, tests taken very close together or a change of laboratory can change the number, which is why the consensus asks for at least 3 tests over 3 months, with the same assay.1 When the calculator shows a warning, take the result as a first estimate.
The European group also leaves out information that matters for the decision, such as the PSA level, the margin in the surgical report and what the PSMA PET shows. The external validation I mentioned was done only after prostatectomy.4 That is why the calculator shows the group and does not tell you which treatment to have.
My approach
After prostatectomy, the first PSA test is done at about 1 month. When the report shows a positive surgical margin and the PSA stays undetectable, I monitor the PSA, as the European guideline advises. When the PSA starts to rise again, I review the series of tests, the surgical report and the scans at the consultation.
After radiotherapy, I perform salvage radical prostatectomy when needed, always robotically, and the decision is made case by case. I also see men for a second opinion when they have had surgery or radiotherapy elsewhere and their PSA is rising. The consultation can be entirely online, in English, with your tests sent in advance, and I start from the tests you already have.
Send your case
If your PSA has started to rise again and you would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
What is PSA doubling time?+
It is the time your PSA takes to double. The PSA Working Group consensus calculates it from the line of the logarithm of PSA over time and recommends reporting it in months.1 It measures how fast the PSA is rising, more than the PSA level itself.
How is PSA doubling time calculated?+
In the consensus, the doubling time is the natural logarithm of 2 divided by the slope of the line of the natural logarithm of PSA against time. The consensus asks for at least 3 values of 0.20 ng/mL or more, over at least 3 months, with at least 4 weeks between tests, all from the same assay and preferably the same laboratory.1 The calculator on this page does the maths.
Is a short doubling time a sign of more serious disease?+
It carries more weight. In the review behind the European guideline groups, PSA recurrence after prostatectomy worsened survival mainly when the doubling time was short and the grade in the surgical report was high.3 In a study of 304 men with rising PSA after prostatectomy, the doubling time helped predict the chance of metastasis and the time until it appeared.5
What are the European risk groups for biochemical recurrence?+
After prostatectomy, risk is high when the doubling time is 1 year or less or the surgical report shows ISUP 4 or 5. After radiotherapy, risk is high when the interval to biochemical failure is 18 months or less or the biopsy showed ISUP 4 or 5. Otherwise, risk is low.2 In a European study of 1,125 men after surgery, the high-risk group had 3.46 times more metastasis and 5.12 times more death from prostate cancer.4
My PSA has risen after surgery. What does the guideline recommend?+
It depends on the PSA level, the surgical report and the doubling time. The European guideline recommends offering monitoring, including PSA, to men in the low-risk group (weak recommendation) and not offering hormone therapy to men without metastases and with a doubling time above 12 months (strong recommendation).2 The plan is decided at the consultation, case by case.
Why does the calculator not show a doubling time when PSA is falling?+
Because with a stable or falling PSA, the slope of the line is zero or negative, so the doubling time does not exist or would be a negative number, as the consensus itself explains.1 In that case, the calculator tells you that your PSA is not rising.
Who can assess a rising PSA after treatment in São Paulo?+
I see men whose PSA is rising after prostatectomy or radiotherapy in São Paulo. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275, and a reference in prostate cancer. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. A second opinion can be done entirely online, in English, with your tests sent in advance. My office is in Vila Mariana.
References
- Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181-2185. PubMed
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment (biochemical recurrence, table 6.4.1). European Association of Urology; 2026. EAU
- Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967-987. PubMed
- Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2019;75(6):896-900. PubMed
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597. PubMed
- Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-439. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
